Single-arm, Open-label, Safety and Efficacy Study of Radioembolization with Yttrium-90 Microspheres in Combination with Durvalumab (MEDI4736) in Locally Advanced and Unresectable Hepatocellular Carcinoma [HCC]) (SOLID)
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Durvalumab (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SOLID
Most Recent Events
- 17 Jul 2023 Results evaluating preliminary efficacy and safety of combination of radioembolization with yttrium-90 microspheres (Y90-radioembolization) and durvalumab, published in the Clinical Cancer Research
- 14 Mar 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases